Bio-Connect
Product image
Product image
Product image

InVivoPlus anti-mouse CTLA-4 (CD152)

Research Use Only
BP0131
Bio X Cell
ApplicationsWestern Blot, Neutralisation/Blocking
Product group Antibodies
ReactivityMouse
Price on request
When logged in and you are part of an academic or non-profit organisation your discount will be shown.
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Bio X Cell
  • Product Name
    InVivoPlus anti-mouse CTLA-4 (CD152)
  • Delivery Days Customer
    7
  • Applications
    Western Blot, Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    9H10
  • Concentration
    4-11 mg/ml
  • Host
    Hamster
  • Isotype
    IgG
  • Scientific Description
    The 9H10 monoclonal antibody reacts with mouse CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. CTLA-4 is a 33 kDa cell surface receptor encoded by the Ctla4 gene that belongs to the CD28 family of the Ig superfamily. CTLA-4 is expressed on activated T and B lymphocytes. CTLA-4 is structurally similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to the B7 family members B7-1 (CD80) and B7-2 (CD86). Upon ligand binding, CTLA-4 negatively regulates cell-mediated immune responses. CTLA-4 plays roles in induction and/or maintenance of immunological tolerance, thymocyte development, and regulation of protective immunity. The critical role of CTLA-4 in immune down-regulation has been demonstrated in CTLA-4 deficient mice, which succumb at 3-5 weeks of age due to the development of a lymphoproliferative disease. CTLA-4 is among a group of inhibitory receptors being explored as cancer treatment targets through immune checkpoint blockade. The 9H10 antibody has been shown to promote T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding.
  • Reactivity
    Mouse
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Ariyan CE et al., 2018 Feb, Cancer Immunol Res
    Read more
  • Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Gao J et al., 2016 Oct 6, Cell
    Read more
  • Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Bartkowiak T et al., 2015 Sep 22, Proc Natl Acad Sci U S A
    Read more
  • Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Spranger S et al., 2015 Jul 9, Nature
    Read more
  • Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Twyman-Saint Victor C et al., 2015 Apr 16, Nature
    Read more
  • Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Stephan SB et al., 2015 Jan, Nat Biotechnol
    Read more
  • Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Oezdemir BC et al., 2014 Jun 16, Cancer Cell
    Read more
  • Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade. Krummey SM et al., 2014 Mar 1, J Immunol
    Read more
  • Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. Goding SR et al., 2013 May 1, J Immunol
    Read more
  • Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. Hervieu A et al., 2013 Feb, J Invest Dermatol
    Read more

Related products

Product image
Product group Antibodies
References
Bio X Cell
ApplicationsFlow Cytometry, Western Blot, Neutralisation/Blocking
ReactivityMouse
  • SizePrice
More sizes
Product image
Product group Antibodies
References
Bio X Cell
  • SizePrice
More sizes
Product image
Product group Chemicals
Bio X Cell
  • SizePrice